The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats

Analyzing real-time PCR data by the comparative CT method

Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190

Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis

Moreau, R., Jalan, R., Ginès, P., Pavesi, M., Angeli, P., Córdoba, J., Durand, F., Gustot, T., Saliba, F., Domenicali, M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.042 · Cited by 3,041

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

Gadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut · doi:10.1136/gut.2010.212159 · Cited by 870 · cited 2×

Tight Junction Pore and Leak Pathways: A Dynamic Duo

Shen, L., Weber, C. R., Raleigh, D. R., Yu, D., & Turner, J. R. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142150 · Cited by 867

Translocation of Certain Indigenous Bacteria from the Gastrointestinal Tract to the Mesenteric Lymph Nodes and Other Organs in a Gnotobiotic Mouse Model

Berg, R. D., & Garlington, A. W. (1979) · Infection and Immunity · doi:10.1128/iai.23.2.403-411.1979 · Cited by 845

Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers.

Madara, J. L., & Stafford, J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113938 · Cited by 758

6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity

Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743

Interferon-γ and Tumor Necrosis Factor-α Synergize to Induce Intestinal Epithelial Barrier Dysfunction by Up-Regulating Myosin Light Chain Kinase Expression

Wang, F., Graham, W. V., Wang, Y., Witkowski, E. D., Schwarz, B. T., & Turner, J. R. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62264-x · Cited by 692

Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction

Yan, M., Hou, L., Cai, Y., Wang, H., Ma, Y., Geng, Q., Jiang, W., & Tang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906452 · Cited by 25

FXR-FGF19 signaling in the gut–liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence

Simbrunner, B., Hofer, B., Schwabl, P., Zinober, K., Petrenko, O., Fuchs, C. D., Semmler, G., Marculescu, R., Mandorfer, M., Datz, C., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10636-4 · Cited by 27

Exclusive Enteral Nutrition Exerts Anti-Inflammatory Effects through Modulating Microbiota, Bile Acid Metabolism, and Immune Activities

Xiao, F., Gao, X., Hu, H., Le, J., Chen, Y., Shu, X., Liang, Z., Xu, Y., Wang, Y., & Zhang, T. (2022) · Nutrients · doi:10.3390/nu14214463 · Cited by 25

Cholestatic liver diseases: An era of emerging therapies

Samant, H. V., Manatsathit, W., Dies, D. F., Shokouh-Amiri, H. M., Zibari, G. B., Boktor, M., & Alexander, J. S. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i13.1571 · Cited by 25

Steroidal or non-steroidal FXR agonists – Is that the question?

Verbeke, L., Nevens, F., & Laleman, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.013 · Cited by 24

Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3

Fan, Y., Ding, W., Zhang, C., Fu, L., Xu, D., & Chen, X. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105911 · Cited by 24

Microbial transformations of bile acids and their receptors in the regulation of metabolic dysfunction-associated steatotic liver disease

Gao, Y., Lin, J., Ye, C., Guo, S., & Jiang, C. (2023) · Liver Research · doi:10.1016/j.livres.2023.09.002 · Cited by 26

The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects

Ronca, V., Davies, S. P., Oo, Y. H., & Lleo, A. (2025) · Hepatology · doi:10.1097/hep.0000000000001225 · Cited by 22

Bile acid signaling in MASLD: From pathogenesis to therapeutic applications

Simbrunner, B., Paternostro, R., Reiberger, T., & Trauner, M. (2025) · Hepatology · doi:10.1097/hep.0000000000001539 · Cited by 30

Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-β1 axis

Tawfiq, R. A., Nassar, N. N., Hammam, O. A., Allam, R. M., Elmazar, M. M., Abdallah, D. M., & Attia, Y. M. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109953 · Cited by 21

Metformin alleviates irradiation-induced intestinal injury by activation of FXR in intestinal epithelia

Yang, J.-Y., Liu, M., Lv, L. L., Guo, J.-R., He, K.-Y., Zhang, H., Wang, K., Cui, C.-Y., Yan, B., Du, D., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.932294 · Cited by 21

Sensitization to autoimmune hepatitis in group VIA calcium-independent phospholipase A2-null mice led to duodenal villous atrophy with apoptosis, goblet cell hyperplasia and leaked bile acids

Li, J., Gan‐Schreier, H., Tuma‐Kellner, S., Stremmel, W., & Chamulitrat, W. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.04.025 · Cited by 21

The emerging microbiome‐based approaches to IBD therapy: From SCFAs to urolithin A

Rudiansyah, M., Jasim, S. A., Azizov, B., Samusenkov, V. O., Abdelbasset, W. K., Yasin, G., Mohammad, H. J., Jawad, M. A., Mahmudiono, T., Hosseini‐Fard, S. R., et al. (2022) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13131 · Cited by 20

The Farnesoid X Receptor Agonist Tropifexor Prevents Liver Damage in Parenteral Nutrition‐fed Neonatal Piglets

Liu, Y., Xiao, Y., Chen, S., Tian, X., Wang, W., Wang, Y., & Cai, W. (2021) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003135 · Cited by 20

Effects of bile acid metabolism on intestinal health of livestock and poultry

Jia, H., & Dong, N. (2024) · Journal of Animal Physiology and Animal Nutrition · doi:10.1111/jpn.13969 · Cited by 19

Celastrol as an intestinal FXR inhibitor triggers tripolide-induced intestinal bleeding: Underlying mechanism of gastrointestinal injury induced by Tripterygium wilfordii

Dai, M., Wan, P., Lin, L., Wu, Z. E., Zhang, T., Zhao, Q., Cheng, Y., Lin, Q., Zhang, B., Liu, A., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155054 · Cited by 19

Pyridoxal isonicotinoyl hydrazone inhibition of FXR is involved in the pathogenesis of isoniazid-induced liver injury

Zhang, G., Chen, L., Wen, Y., Rao, Z., Wei, Y., & Wu, X. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115134 · Cited by 19

The gut-liver axis in hepatobiliary diseases

Ichikawa, M., Okada, H., Nakamoto, N., Taniki, N., Chu, P., & Kanai∥, T. (2024) · Inflammation and Regeneration · doi:10.1186/s41232-023-00315-0 · Cited by 19

Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation

Hao, Y., Hao, Z., Zeng, X., & Lin, Y. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02134-7 · Cited by 18

Role of Bile Acids and Gut Microbiota in Parenteral Nutrition Associated Injury

Manithody, C., van Nispen, J., Murali, V., Jain, S., Ashish, S., Armstrong, A. T., & Ajay, J. (2020) · Journal of Human Nutrition · doi:10.36959/487/286 · Cited by 18

Improved hemodynamic and liver function in portal hypertensive cirrhotic rats after administration of B. pseudocatenulatum CECT 7765

Gómez‐Hurtado, I., Zapater, P., Portune, K. J., Juanola, O., Fernández‐Iglesias, A., González-Navajas, J. M., Gracia‐Sancho, J., Sanz, Y., & Francés, R. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1709-y · Cited by 18

Orchestration of Gut–Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation

Liu, A., Huang, M., Xi, Y., Deng, X., & Xu, K. (2025) · Biomedicines · doi:10.3390/biomedicines13061422 · Cited by 17

Microbial bile acid modifications: current understandings, key problems, and future perspectives

Zhang, H., Wen, J., Liu, X., Feng, Y., Liu, X., & Ning, K. (2025) · Science China Life Sciences · doi:10.1007/s11427-025-3019-2 · Cited by 20

Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome

Pereira-Fantini, P. M., Lapthorne, S., Gahan, C. G. M., Joyce, S. A., Charles, J., Fuller, P. J., & Bines, J. E. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.02.008 · Cited by 17

Obeticholic Acid Derivative, T-2054 Suppresses Osteoarthritis via Inhibiting NF-κB-Signaling Pathway

Guo, D., He, L., Gao, Y., Jin, C., Lin, H., Zhang, L., Wang, L., Zhou, Y. Y., Yao, J., Duan, Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083807 · Cited by 16

Therapeutic implications of obeticholic acid, a farnesoid X receptor agonist, in the treatment of liver fibrosis

Azizsoltani, A., Niknam, B., Taghizadeh-Teymorloei, M., Ghoodjani, E., Dianat-Moghadam, H., & Alizadeh, E. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118249 · Cited by 15

Bile acid disorders and intestinal barrier dysfunction are involved in the development of fatty liver in laying hens

Zhao, L., Jiang, Q., Lei, J., Cui, J., Pan, X., Yuan, Y., & Zhang, B. (2024) · Poultry Science · doi:10.1016/j.psj.2024.104422 · Cited by 18

Liver cirrhosis and complications from the perspective of dysbiosis

Nie, G., Zhang, H., Xie, D., Yan, J., & Li, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1320015 · Cited by 16

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis

Namisaki, T., Moriya, K., Kitade, M., Takeda, K., Kaji, K., Okura, Y., Shimozato, N., Sato, S., Nishimura, N., Seki, K., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1104 · Cited by 15

Microbial Infections as a Trigger for Acute-on-Chronic Liver Failure: A Review

Cai, Q., Liu, W., Zhu, M., & Sheng, J. (2019) · Medical Science Monitor · doi:10.12659/msm.915637 · Cited by 17

The protective effect of obeticholic acid on lipopolysaccharide-induced disorder of maternal bile acid metabolism in pregnant mice

Zhang, C., Gan, Y., Lv, J.-W., Qin, M.-Q., Hu, W., Liu, Z.-B., Ma, L., Song, B., Li, J., Jiang, W., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106442 · Cited by 15

Duodenal bile acids as determinants of intestinal mucosal homeostasis and disease

Keely, S., & Talley, N. J. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13854 · Cited by 15

Traditional Chinese medicine to improve immune imbalance of asthma: focus on the adjustment of gut microbiota

Ke, L., Li, C., Men, J., Xu, B., Yang, C., Yan, P., Gai, Z., Zhang, Q., & Zhang, L. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1409128 · Cited by 15

Targeting Bile-Acid Metabolism: Nutritional and Microbial Approaches to Alleviate Ulcerative Colitis

Jiang, X., Ren, J., Yu, G., Wu, W., Chen, M., Zhao, Y., & He, C. (2025) · Nutrients · doi:10.3390/nu17071174 · Cited by 16

Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities

Zhou, H., Huang, Y., Chen, C., Song, M., & Hylemon, P. B. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100120 · Cited by 17

Obeticholic acid protects against lithocholic acid-induced exogenous cell apoptosis during cholestatic liver injury

Lu, Q., Zhu, Y., Wang, C., Zhang, R., Miao, Y., Chai, Y., Jiang, Z., & Yu, Q. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122355 · Cited by 14

Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda

Ferguson, J., Solà, E., Perez, M. A., Piano, S. S., Cheng, A. G., Subramanian, A. K., & Kim, W. R. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000539 · Cited by 15

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis

Namisaki, T., Kaji, K., Shimozato, N., Kaya, D., Ozutsumi, T., Tsuji, Y., Fujinaga, Y., Kitagawa, K., Furukawa, M., Sato, S., et al. (2022) · Indian Journal of Gastroenterology · doi:10.1007/s12664-021-01220-5 · Cited by 13

Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension

Kalo, E., Read, S. A., & Ahlenstiel, G. (2021) · Livers · doi:10.3390/livers1030014 · Cited by 12

Bovine milk osteopontin improved intestinal health of pregnant rats fed a high-fat diet through improving bile acid metabolism

Han, L., Li, Q., Du, ‬., & Mao, X. (2023) · Journal of Dairy Science · doi:10.3168/jds.2023-23802 · Cited by 13

Suppressing FXR promotes antiviral effects of bile acids via enhancing the interferon transcription

Liang, X., Liu, K., Jia, X., Cheng, C., Zhang, M., Kong, L., Li, Q., Liu, Z., Li, M., Li, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.005 · Cited by 12

FXR crosstalk with other nuclear receptors

Mohammed, T. A., & Zalzala, M. H. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01118-2 · Cited by 14

Alleviation of cholestatic liver injury and intestinal permeability by lubiprostone treatment in bile duct ligated rats: role of intestinal FXR and tight junction proteins claudin-1, claudin-2, and occludin

Safari, F., Sharifi, M., Talebi, A., Mehranfard, N., & Ghasemi, M. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02455-z · Cited by 12

Activation of the Nuclear Receptor Fxr Improves Intestinal Cell Tolerance to Ischemia–Reperfusion Injury

Wang, X., Li, S., Chen, M., Liu, J., Dong, R.-R., Wang, H.-M., & Zhu, S.-G. (2017) · Shock · doi:10.1097/shk.0000000000001019 · Cited by 9

Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis

Shimozato, N., Namisaki, T., Kaji, K., Kitade, M., Okura, Y., Sato, S., Moriya, K., Seki, K., Kawaratani, H., Takaya, H., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13385 · Cited by 12

Fermented bile acids improved growth performance and intestinal health by altering metabolic profiles and intestinal microbiome in Micropterus salmoides

Guo, Q., Liú, W., Zhao, L., Sui, Y., Zhao, H., Liu, Y., Mu, C., & Wang, X. (2024) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2024.109593 · Cited by 11

Obeticholic acid differentially regulates hepatic injury and inflammation at different stages of D-galactosamine/lipopolysaccharide-evoked acute liver failure

Ding, W., Fan, Y., Zhang, C., Fu, L., Chen, X., & Xu, D. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.02.011 · Cited by 11

Review article: insights into the bile acid‐gut microbiota axis in intestinal failure‐associated liver disease—redefining the treatment approach

Wang, Y., Zheng, L., Zhou, Z., Yao, D., Huang, Y., Liu, B., Duan, Y., & Li, Y. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16676 · Cited by 12

Beyond lipids: Novel mechanisms for parenteral nutrition–associated liver disease

Wichman, B. E., Nilson, J., Govindan, S., Chen, A., Jain, A., Arun, V., Derdoy, J., Krebs, J., & Jain, A. K. (2022) · Nutrition in Clinical Practice · doi:10.1002/ncp.10830 · Cited by 11

Bile Acids in Control of the Gut-Liver-Axis

Hild, B., Heinzow, H. S., Schmidt, H., & Maschmeier, M. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1330-9644 · Cited by 10

Modulating intestinal barrier function by sphingosine-1-phosphate receptor 1 specific agonist SEW2871 attenuated ANIT-induced cholestatic hepatitis via the gut-liver axis

Yang, T., Li, L., Pang, J., Cai, H., Wei, C., Wang, X., Xia, Z., Huang, X., Zhang, L., & Jiang, Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111150 · Cited by 10

Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites

Yan, K. G., Hung, A., Parmer, C. M., Yang, H., Jain, D., Lim, B., Goodman, A. L., & García–Tsao, G. (2021) · Hepatology Communications · doi:10.1002/hep4.1740 · Cited by 10

Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis

Fuchs, C. D., Halilbasic, E., & Trauner, M. A. (2017) · Clinical Liver Disease · doi:10.1002/cld.613 · Cited by 9

Future Medical Treatment of PSC

Krones, E., Marschall, H., & Fickert, P. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00454-4 · Cited by 9

Lizhong Decoction Ameliorates Ulcerative Colitis in Mice via Regulation of Plasma and Urine Metabolic Profiling

Wang, L., Tao, J., Chen, Y., Shen, Y., & Jiang, S. (2021) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-021-3299-4 · Cited by 9

Pentacyclic triterpenes modulate farnesoid X receptor expression in colonic epithelial cells: Implications for colonic secretory function

Fallon, C. M., Smyth, J. S., Quach, A., Lajczak, N., O’Toole, A., Barrett, K. E., Sheridan, H., & Keely, S. J. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102569 · Cited by 9

Simulating the Post-gastric Bypass Intestinal Microenvironment Uncovers a Barrier-Stabilizing Role for FXR

Hankir, M. K., Langseder, T., Bankoglu, E. E., Ghoreishi, Y., Dischinger, U., Kurlbaum, M., Kroiß, M., Otto, C., le Roux, C. W., Arora, T., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101777 · Cited by 8

The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives

Gitto, S., Guarneri, V., Sartini, A., & Andreoné, P. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1399060 · Cited by 8

Lactococcus garvieae aggravates cholestatic liver disease by increasing intestinal permeability and enhancing bile acid reabsorption

Liu, M., Ji, Y.-L., Hu, Y., Su, Y.-X., Yang, J., Wang, X., Chu, H.-Y., Zhang, X., Dong, S., Yang, H., et al. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i10.101014 · Cited by 8

Stroke-Associated Pneumonia and the Brain-Gut-Lung Axis

Bai, J., Zhao, Y., Wang, Z., Qin, P., Huang, J., Cheng, Y., Wang, C., Chen, Y., Liu, L., Zhang, Y., et al. (2025) · The Neurologist · doi:10.1097/nrl.0000000000000626 · Cited by 8

Analyzing the gut liver axis: a dual role of the microbiome in the genesis, progression, and treatment of liver cell carcinoma

Li, Q., & Liu, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1701101 · Cited by 7

Pleiotropic immunoregulation by bile acids in pathophysiology

Lin, B.-S., Yin, M., Xie, S.-A., Li, P., & Li, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1719092 · Cited by 8

Intestinal Farnesoid X Receptor Modulates Duodenal Surface Area but Does Not Control Glucose Absorption in Mice

Yang, J., van Dijk, T. H., Koehorst, M., Havinga, R., de Boer, J. F., Kuipers, F., & van Zutphen, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044132 · Cited by 7

Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies

Curto, A., Iamello, R. G., Lynch, E. N., & Galli, A. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i30.109028 · Cited by 6

FXR agonists for colorectal and liver cancers, as a stand-alone or in combination therapy

Yu, D., Lu, Z., Wang, R., Xiang, Y., Li, H., Lu, J., Zhang, L., Chen, H., Li, W., Luan, X., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115570 · Cited by 7

Bile acids as gatekeepers: Orchestrating gut-liver axis for metabolic and immune balance

Chen, Q., Xin, L. I. U., & Jiang, Z.-H. (2026) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2026.01.001 · Cited by 6

Critical Role of Cholic Acid in the Development of iHFC Diet-induced MASH in TSNO Mice

Goto, K., Kani, K., Kato, M., Igarashi, N., Tada, Y., Kasai, K., Ichimura‐Shimizu, M., Watanabe, S., Tsuneyama, K., Furusawa, Y., et al. (2025) · Inflammation · doi:10.1007/s10753-025-02294-5 · Cited by 5

Gut microbial profiling as a therapeutic and diagnostic target for managing primary biliary cholangitis.

Floreani, A., Martin, S. D., Ikeura, T., Okazaki, K., & Gershwin, M. E. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1865917 · Cited by 5

Evolving insights in the pathophysiology of complications of cirrhosis: The farnesoid X receptor (FXR) to the rescue?

Laleman, W., Trebicka, J., & Verbeke, L. (2016) · Hepatology · doi:10.1002/hep.28771 · Cited by 5

The Gastrointestinal Barrier—Mechanisms of Barrier Dysfunction in Liver Cirrhosis and Spontaneous Bacterial Peritonitis

Olaru-Stavila, C., Steinmann, S. M., Mester, P., Müller, M., Tcaciuc, E., & Gülow, K. (2026) · Biomedicines · doi:10.3390/biomedicines14051084 · Cited by 5

Intraduodenal fecal microbiota transplantation ameliorates gut atrophy and cholestasis in a novel parenteral nutrition piglet model

Manithody, C., Denton, C., Mehta, S., Carter, J., Kurashima, K., Bagwe, A., Swiderska‐Syn, M., Guzmán, M. A., Besmer, S., Jain, S., et al. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00012.2024 · Cited by 4

Investigating intestinal farnesoid X receptor functions at the intestinal mucosal barrier and in the intestinal microbiota in a biliary obstruction mouse model

Cai, Y., Chen, X., Wang, H., Hou, L., Zheng, R., Wang, Y., Jiang, W., & Tang, W. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2024 · Cited by 4

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation

Tornai, D., Balogh, B., Csillag, A., Budai, A., Kiss, A., Antal‐Szalmás, P., Méhes, G., Baráth, L., Tornai, T., Tornai, I., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70481 · Cited by 4

Probiotic-derived extracellular vesicles attenuate cholestatic liver damage via gut-liver axis

Liu, X., Wang, Y., Medina, A. A., Liu, D., Liu, J., Tang, W., Wang, M., Chen, X., Huang, K., Liu, M., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108152 · Cited by 4

Effects of dietary of bile acid on growth performance, antioxidant capacity, liver and intestinal health and immune function in loach (Misgurnus anguillicaudatus)

Liu, H., Zhang, X., Li, K., Fang, Q., Liu, X., Sun, L. Y., Guo, G.-L., An, S., Li, M., Wang, G., et al. (2024) · Aquaculture Reports · doi:10.1016/j.aqrep.2024.102455 · Cited by 4

Pathologic and therapeutic insights into cholestatic liver disease-associated depressive disorder

Li, X., Wang, H., Li, Y., Huang, M., Li, X., Yu, Z., Li, P., & Liu, R. (2025) · Acta Materia Medica · doi:10.15212/amm-2024-0082 · Cited by 6

The expanding role of the bile acid receptor farnesoid X in the intestine and its potential clinical implications

Ceulemans, L. J., Canovai, E., Verbeke, L., Pirenne, J., & Farré, R. (2016) · Acta chirurgica Belgica · doi:10.1080/00015458.2016.1215953 · Cited by 4

FXR Stimulation by Obeticholic Acid Treatment Restores Gut Mucosa Functional and Structural Integrity in Individuals With Altered Glucose Tolerance

Vito, F. D., Marasco, R., Suraci, E., Facciolo, A., Hribal, M. L., Sesti, G., Andreozzi, F., Luzza, F., & Fiorentino, T. V. (2025) · Diabetes · doi:10.2337/db25-0035 · Cited by 4

Amentoflavone ameliorates DSS-induced ulcerative colitis via gut microbiota-bile acid metabolism axis modulation

Chen, Y., Li, K., Zhang, M., Liu, J., Wang, M., Xiu, Y.-H., Zhang, Q.-Y., & Zhao, D. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106706 · Cited by 2

Role of Intestinal Barrier Disruption to Acute-on-Chronic Liver Failure

Pohl, J., Aretakis, D., Tacke, F., Engelmann, C., & Sigal, M. J. (2025) · Seminars in Liver Disease · doi:10.1055/a-2516-2361 · Cited by 3

Role of Bile Acids and Nuclear Receptors in Acupuncture in Improving Crohn’s Disease

Shen, J., Qi, Q., Han, D., Liu, S., Huang, R., Zhu, Y., Zheng, H., Gu, K., Wu, H., & Liu, H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5814048 · Cited by 3

The Microbiota‐Derived Metabolite Deoxycholic Acid Regulates Enteric Neuron Activity and Connectivity

Dréan, M. E. L., Ganachaud, B., Rebion, M., Marchix, J., Berre‐Scoul, C. L., Hulin, P., Feyeux, M., Talon, S., Neunlist, M., Caillaud, M., et al. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70351 · Cited by 2

Traditional Chinese Medicine Modulation of the Gut–Liver Axis: From Barrier Disruption to Inflammasome Activation in MASLD/MASH

Ren, L., He, Q., Hu, Z., Jin, J., & 陶飞宝 (2026) · Journal of Visualized Experiments · doi:10.3791/70259 · Cited by 2

Microbiota in cholestatic diseases: crosstalk among bile composition, the biliary microbiome, and host immunity

Yang, Y., Ren, L., Zhang, Y., Wang, X., Shang, J., & Zhang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1884030 · Cited by 2

Infektionen und Leberzirrhose

Dibos, M., Mayr, U., Triebelhorn, J., Schmid, R. M., & Lahmer, T. (2024) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-024-01168-2 · Cited by 2

Microbiota, Inflammation, and Gut Barrier Dysfunction in HCC

Ram, A. K., Wright, G. A. K., & Vairappan, B. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.89578 · Cited by 2

Novel Approaches to Reducing the Risk of Variceal Hemorrhage

Nevens, F. (2017) · Digestive Diseases · doi:10.1159/000456594 · Cited by 2

Intestinal mucus and gut-vascular barrier: FxR-modulated entry sites for pathological bacterial translocation in liver cirrhosisPreprint

Sorribas, M., Jakob, M. O., Yilmaz, B., Li, H., Stutz, D., Noser, Y., Gottardi, A. D., Moghadamrad, S., Hassan, M., Albillos, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/690057 · Cited by 2

Pathophysiologic Basis for Alternative Therapies for Cholestasis

Fuchs, C. D., Halilbasic, E., & Trauner, M. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch30 · Cited by 2

Emerging Targets for the Treatment of Primary Sclerosing Cholangitis

Tatscher, E., Mady, S., & Fickert, P. (2025) · Seminars in Liver Disease · doi:10.1055/a-2601-9426 · Cited by 1

Disease duration impacts intestinal gene expression profiles in Crohn’s disease but not in ulcerative colitis

Ibing, S., Tastad, C., Renard, B. Y., Cohen, L. J., Argmann, C., Helmus, D. S., Schadt, E. E., Mérad, M., Kukreja, A., Visvanathan, S., et al. (2025) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf179 · Cited by 2

Changes in bone characteristics precede serum mineral deterioration in a mouse model of early stage chronic kidney disease

Verlinden, L., Stockmans, I., Moermans, K., & Carmeliet, G. (2026) · JBMR Plus · doi:10.1093/jbmrpl/ziag017 · Cited by 1

Bile acid metabolism and signaling in human and animal health: A One Health perspective

Li, L., Liu, S., Cao, Z., Cao, Y., Wu, S., Deng, L., Yao, J., & Zhang, J. (2026) · iMetaOmics. · doi:10.1002/imo2.70123 · Cited by 1

The Gut Microbiome and Cirrhosis: Basic Aspects

Wiest, R. (2015) · Springer eBooks · doi:10.1007/978-3-319-23018-4_18 · Cited by 2

Investigating Fibroblast Growth Factor 19 expression in primary and secondary bile acid diarrhoea

Nolan, J. (2016) · doi:10.25560/41879 · Cited by 1

Functional Changes of Paneth Cells in the Intestinal Epithelium of Mice with Obstructive Jaundice and After Internal and External Biliary Drainage

Tian, X.-P., Zhang, Z., & Li, W. (2019) · Current Molecular Medicine · doi:10.2174/1566524019666190820141331 · Cited by 1

Increased membrane permeation and blood concentration of 6‐carboxyfluorescein associated with dysfunction of paracellular route barrier in the small intestine of ulcerative colitis model rats

Kumagai, M., Ishii, M., Morimoto, K., & Tomita, M. (2020) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2220 · Cited by 1

Potential Antifibrotic Therapies: Approaching the Bedside: Proof-of-Concept Studies (Part 1)

Laleman, W. (2015) · Springer eBooks · doi:10.1007/978-3-319-23018-4_15

Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis

Schierwagen, R., Uschner, F. E., Klein, S., & Trebicka, J. (2016) · Current Hepatology Reports · doi:10.1007/s11901-016-0321-y

Animal Models When Examining the Gut-Liver Axis

Magdaleno, F., Brol, M. J., Schierwagen, R., Uschner, F. E., Zwick, M., & Trebicka, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-98890-0_14

Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction

Yan, M., Hou, L., Cai, Y., Wang, H., Ma, Y., Geng, Q., Jiang, W., & Tang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906452 · Cited by 25

Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats

Úbeda, M., Lario, M., Muñoz, L., Borrero, M.-J., Rodríguez-Serrano, M., Sánchez-Díaz, A.-M., del Campo, R., Lledó, L., Pastor, Ó., García-Bermejo, L., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.12.010 · Cited by 178

Exploring the tissue specific roles of FXR within the gut-liver axis: Insights from a novel mouse model

Ludwigs, L., Reul, T., Henniges, A., Volkert, I., Peltzer, M., Becker, S., Molinario, A., Marshall, H.-U., Edlund, K., Hengstler, J. G., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-1777487

FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease

Koelfat, K. V. K., Visschers, R. G. J., Hodin, C. M. I. M., de Waart, D. R., van Gemert, W. G., Cleutjens, J. P. M., Gijbels, M. J., Shiri‐Sverdlov, R., Mookerjee, R. P., Lenaerts, K., et al. (2017) · Journal of Clinical and Translational Research · doi:10.18053/jctres.03.201703.004 · Cited by 9

Investigating intestinal farnesoid X receptor functions at the intestinal mucosal barrier and in the intestinal microbiota in a biliary obstruction mouse model

Cai, Y., Chen, X., Wang, H., Hou, L., Zheng, R., Wang, Y., Jiang, W., & Tang, W. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2024 · Cited by 4